The Effectiveness of Intravenous Golimumab Administered Directly After Infliximab in Rheumatoid Arthritis Patients
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-6901
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
The Effectiveness of Intravenous Golimumab Administered Directly After Infliximab in Rheumatoid Arthritis Patients ; volume:18 ; number:3 ; day:28 ; month:7 ; year:2018 ; pages:211-219 ; date:9.2018
Drugs in R & D ; 18, Heft 3 (28.7.2018), 211-219, 9.2018
- Urheber
-
Bray, Vance J.
- Beteiligte Personen und Organisationen
-
Broadwell, Aaron
Baraf, Herbert S. B.
Black, Shawn
Brady, Brenna L.
Tkacz, Joseph
Yarngo, Lorraine
DeHoratius, Raphael J.
SpringerLink (Online service)
- DOI
-
10.1007/s40268-018-0240-1
- URN
-
urn:nbn:de:101:1-2018102723302790374616
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:45 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Bray, Vance J.
- Broadwell, Aaron
- Baraf, Herbert S. B.
- Black, Shawn
- Brady, Brenna L.
- Tkacz, Joseph
- Yarngo, Lorraine
- DeHoratius, Raphael J.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Improvement in disease activity among patients with rheumatoid arthritis who switched from intravenous infliximab to intravenous golimumab in the ACR RISE registry
Subcutaneous infliximab in Crohn’s disease patients with previous immunogenic failure of intravenous infliximab
Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment
Incidence of Infusion Reactions and Clinical Effectiveness of Intravenous Golimumab Versus Infliximab in Patients with Rheumatoid Arthritis: The Real-World AWARE Study
Response to Treatment with Intravenous Golimumab or Infliximab in Rheumatoid Arthritis Patients: PROMIS Results from the Real-World Observational Phase 4 AWARE Study
Pharmacokinetics of Oral and Intravenous Paracetamol (Acetaminophen) When Co-Administered with Intravenous Morphine in Healthy Adult Subjects
Infliximab concentration monitoring improves the control of disease activity in rheumatoid arthritis
Gene profiling in white blood cells predicts infliximab responsiveness in rheumatoid arthritis
Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study
The acute phase reactant orosomucoid-2 directly promotes rheumatoid inflammation
The effects of infliximab therapy on the serum proteome of rheumatoid arthritis patients
Administration costs of intravenous biologic drugs for rheumatoid arthritis
Improvement in disease activity among patients with rheumatoid arthritis who switched from intravenous infliximab to intravenous golimumab in the ACR RISE registry
Subcutaneous infliximab in Crohn’s disease patients with previous immunogenic failure of intravenous infliximab
Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment
Incidence of Infusion Reactions and Clinical Effectiveness of Intravenous Golimumab Versus Infliximab in Patients with Rheumatoid Arthritis: The Real-World AWARE Study
Response to Treatment with Intravenous Golimumab or Infliximab in Rheumatoid Arthritis Patients: PROMIS Results from the Real-World Observational Phase 4 AWARE Study
Pharmacokinetics of Oral and Intravenous Paracetamol (Acetaminophen) When Co-Administered with Intravenous Morphine in Healthy Adult Subjects
Infliximab concentration monitoring improves the control of disease activity in rheumatoid arthritis
Gene profiling in white blood cells predicts infliximab responsiveness in rheumatoid arthritis
Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study
The acute phase reactant orosomucoid-2 directly promotes rheumatoid inflammation
The effects of infliximab therapy on the serum proteome of rheumatoid arthritis patients
Administration costs of intravenous biologic drugs for rheumatoid arthritis
Improvement in disease activity among patients with rheumatoid arthritis who switched from intravenous infliximab to intravenous golimumab in the ACR RISE registry
Subcutaneous infliximab in Crohn’s disease patients with previous immunogenic failure of intravenous infliximab
Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment
Incidence of Infusion Reactions and Clinical Effectiveness of Intravenous Golimumab Versus Infliximab in Patients with Rheumatoid Arthritis: The Real-World AWARE Study
Response to Treatment with Intravenous Golimumab or Infliximab in Rheumatoid Arthritis Patients: PROMIS Results from the Real-World Observational Phase 4 AWARE Study
Pharmacokinetics of Oral and Intravenous Paracetamol (Acetaminophen) When Co-Administered with Intravenous Morphine in Healthy Adult Subjects
Infliximab concentration monitoring improves the control of disease activity in rheumatoid arthritis
Gene profiling in white blood cells predicts infliximab responsiveness in rheumatoid arthritis
Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study
The acute phase reactant orosomucoid-2 directly promotes rheumatoid inflammation
The effects of infliximab therapy on the serum proteome of rheumatoid arthritis patients